Sana Biotechnology, Inc.
SANA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SANA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SANA
Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell medicines using its hypoimmune (HIP) platform for type 1 diabetes, B-cell mediated autoimmune diseases, and refractory B-cell malignancies.
Key risk: Going concern uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 7 pipeline candidates · 5 clinical trials for Sana Biotechnology, Inc..
Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell medicines using its hypoimmune (HIP) platform for type 1 diabetes, B-cell mediated autoimmune diseases, and refractory B-cell malignancies.
- Sana Biotechnology focuses on ex vivo and in vivo cell engineering platforms, including hypoimmune allogeneic CAR T cells and stem-cell derived therapies [sec_mda · as of 2024-02-29].
- In November 2024, the company announced a portfolio prioritization to focus on type 1 diabetes, B-cell mediated autoimmune diseases, refractory B-cell malignancies, and the fusogen platform for in vivo CAR T cells, while suspending development of SC291 and SC379 [sec_mda · as of 2025-03-17].
- As of June 30, 2026, the company reported cash and equivalents of $61.3 million, a net loss of $63.6 million, and shareholders' equity of $160.9 million [sec].
- Management has expressed substantial doubt about the company's ability to continue as a going concern, stating that present capital resources may not be sufficient to fund planned operations for at least one year [sec_mda · as of 2025-03-17].
- The company expects to incur additional losses for the foreseeable future as it conducts research, clinical trials, and manufacturing activities [sec_mda · as of 2025-08-11].
What works
- Sana's hypoimmune (HIP) platform is designed to enable allogeneic cell therapies that evade immune rejection, potentially allowing off-the-shelf treatments [sec_mda · as of 2024-02-29].
- The company has a broad pipeline with multiple programs targeting large markets such as type 1 diabetes and autoimmune diseases, each offering potential standalone value [sec_mda · as of 2024-02-29].
- Sana is advancing a fusogen platform for in vivo CAR T cell generation, which could simplify treatment by eliminating the need for ex vivo cell engineering [sec_mda · as of 2025-03-17].
What to weigh
- Sana has a limited cash runway; as of June 30, 2026, it held $61.3 million in cash and equivalents and reported a net loss of $63.6 million for the quarter, indicating ongoing cash burn [sec].
- Management has identified substantial doubt about the company's ability to continue as a going concern, noting that existing capital may not be sufficient for 12 months of operations [sec_mda · as of 2025-03-17].
- The company has suspended development of two key programs (SC291 and SC379) and is seeking partnerships, reflecting pipeline attrition and strategic uncertainty [sec_mda · as of 2025-03-17].
- Sana is in early stages of development across its pipeline and faces typical risks of clinical-stage biotech, including unforeseen expenses, delays, and regulatory hurdles [sec_mda · as of 2024-02-29].
From the filings
Quoted directly from source documents.
Sana's portfolio prioritization in November 2024 focused on type 1 diabetes, B-cell mediated autoimmune diseases, refractory B-cell malignancies, and the fusogen platform.
“In November 2024, we announced a portfolio prioritization to prioritize clinical and preclinical development in type 1 diabetes, B-cell mediated autoimmune diseases, refractory B-cell malignancies, and the fusogen platform for generating in vivo CAR T cells.”
SEC MD&A · March 17, 2025
Management has substantial doubt about the company's ability to continue as a going concern.
“Management has determined that our present capital resources may not be sufficient to fund our planned operations for at least one year from the date of this Annual Report, and there is substantial doubt as to our ability to continue as a going concern.”
SEC MD&A · March 17, 2025
Sana expects to incur additional losses for the foreseeable future.
“We expect to incur additional losses for the foreseeable future as we conduct our research and development efforts, including conducting clinical trials and preclinical studies, developing new product candidates, continuing to establish our external manufacturing capabilities, and funding our operations generally.”
SEC MD&A · August 11, 2025
Sana's platforms include hypoimmune allogeneic CAR T cells and stem-cell derived therapies.
“We continue to make progress developing our ex vivo cell engineering platforms - our hypoimmune allogeneic CAR T cell platform and our stem-cell derived platform that also leverages our HIP technology.”
SEC MD&A · February 29, 2024
Risks & what to watch (4)›
Key risks
- Going concern uncertainty — Management has substantial doubt about the company's ability to continue as a going concern due to insufficient capital [sec_mda · as of 2025-03-17].
- Cash runway limited — Cash and equivalents of $61.3M as of June 30, 2026, with a quarterly net loss of $63.6M, indicating a short runway [sec].
- Pipeline attrition — Suspension of SC291 and SC379 programs and reliance on partnerships for those assets introduces execution risk [sec_mda · as of 2025-03-17].
- Early-stage development — All product candidates are in early preclinical or clinical stages, with no approved products and high risk of failure [sec_mda · as of 2024-02-29].
What to watch
- Progress of clinical trials in type 1 diabetes and B-cell mediated autoimmune diseases [sec_mda · as of 2025-03-17].
- Updates on the fusogen platform for in vivo CAR T cells [sec_mda · as of 2025-03-17].
- Ability to secure additional financing or partnerships to extend cash runway [sec_mda · as of 2025-03-17].
- Outcome of partnership efforts for suspended programs SC291 and SC379 [sec_mda · as of 2025-03-17].
Sources: SEC MD&A · Generated August 26, 2026 · How we verify sources →
Run Sana Biotechnology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Sana Biotechnology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
14.8 months
D/E 1.79 · 0% dilution
Lead: Phase 1
7 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
198
Total value held
$471.2M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 37,430,284 | $107.8M |
| flagship pioneering, llc | 25,001,856 | $72.0M |
| vanguard capital management llc | 14,869,448 | $42.8M |
| blackrock, inc. | 14,240,175 | $41.0M |
| state street corp | 10,538,086 | $30.3M |
| canada pension plan investment board | 10,221,900 | $29.4M |
| geode capital management, llc | 4,181,973 | $12.0M |
| marex group plc | 3,999,100 | $11.5M |
| goldman sachs group inc | 3,181,115 | $9.2M |
| bank of america corp /de/ | 2,946,861 | $8.5M |
Showing top 10 of 198 institutional holders of Sana Biotechnology, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 27.8%
- Days to cover
- 11.5
- Shares short
- 41,091,249
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SANA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Sana Biotechnology, Inc.?
Sana Biotechnology, Inc. is a clinical-stage biotechnology company developing engineered cell medicines using its hypoimmune (HIP) platform for type 1 diabetes, B-cell mediated autoimmune diseases, and refractory B-cell malignancies.
What is Sana Biotechnology, Inc.'s lead drug candidate?
Sana Biotechnology, Inc.'s most advanced tracked candidate is sc255 (Preclinical) for Multiple myeloma (MM).
Who is the CEO of Sana Biotechnology, Inc.?
Dr. Steven D. Harr M.D. is the chief executive officer of Sana Biotechnology, Inc. (SANA).
Where is Sana Biotechnology, Inc. headquartered?
Sana Biotechnology, Inc. (SANA) is headquartered in Seattle, WA, United States.
What therapeutic areas does Sana Biotechnology, Inc. focus on?
Sana Biotechnology, Inc. develops therapies across Oncology, Rare Disease, Gene Therapy, Immunology, Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.